# Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

> **NCT01508806** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 30 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide

## Key facts

- **NCT ID:** NCT01508806
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508806, "Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01508806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*